ÚHKT - Ústav hematologie a krevní transfuze
Úsek pro vědu a výzkum

Treated diagnoses

Tumor, congenital and very rare diseases

At UHKT we deal with blood formation disorders in their full scope. Our care thus covers both congenital and acquired non-tumor diseases (anemia, coagulation disorders, etc.), as well as tumor diseases such as leukemia or myelodysplastic syndrome. Moreover, many of the diagnoses we treat here are very rare. This means that only tens of people in the entire Czech Republic suffer from it.
The treatment procedure here is therefore strictly governed by international and national protocols. At the same time, we often enroll patients in appropriate clinical trials, if available.
Therapy usually includes several cycles of chemotherapy, targeted biological treatment, immunological, immunosuppressive and device-based treatment (TPE and depletion procedures performed in collaboration with the UHKT apheresis department) and also various forms of blood-forming cell transplantation.

Most common diagnoses:

Acute myeloid leukemia (AML) and lymphoblastic leukemia (ALL)

  • The number of newly diagnosed and intensively treated patients on the inpatient ward is approximately 40 per year. The age of these patients was 20 to 68 years
  • In 84 percent of patients, we usually achieve disease remission (so-called remission) after two cycles of chemotherapy
  • Approximately 20 to 30 percent of these patients must still be indicated for bone marrow transplantation in the same year

Myelodysplastic syndrome (MDS)

  • Myelodysplastic syndrome represents proliferation of a pathological clone of hematopoietic cells, which can result in acute leukemia
  • Early stages of the disease are treated mostly on an outpatient basis, advanced stages often require hospitalization with special treatment including hematopoietic cell transplantation
  • The incidence of the disease increases in people over 60 years of age, incidence is 4.5 patients per 100 thousand inhabitants

Chronic myeloid leukemia (CML)

  • This disease accounts for 20 to 25% of all adult leukemias and the number of newly detected cases is 1-1.5 per 100 thousand inhabitants per year
  • Every year approximately 30 patients are diagnosed at our facility, currently we are treating almost 400 patients
  • Very effective targeted therapy with so-called tyrosine kinase inhibitors (TKI) has significantly improved their prognosis, restores patients to full-fledged life and does not essentially shorten their life expectancy.

Hemophilia

  • The most common type of blood coagulation disorder in the Czech Republic affects approximately one thousand people
  • Treatment usually occurs on an outpatient basis by administering the missing coagulation factor
  • The number of bleeds is significantly reduced thanks to modern treatment
Other treated diagnoses:
  • Myeloproliferative disease 
  • Chronic lymphoblastic leukemia
  • Severe forms of hemolytic anemia, aplastic anemia
  • Complications related to administered treatment (infections, viral reactivations, graft-versus-host reaction)